

## SUPPLEMENTARY MATERIALS

### Supplementary figures

**Figure S1.** Sequence alignment of the fusion protein (Signal peptide-FaeG Nanobody-ProtA) expressed in *Lactococcus lactis*. The highlighted sections show the Usp signal peptide (green), anti-FaeG nanobody sequences (blue) and the ProtA sequences (red). The long and short ProtA repeat (consensus EDNNKPGK) sequences are indicated in italic. The LPETG C-terminal motif, recognized by the sortase enzyme, is shown in bold. Dashes were introduced to align the amino acid sequences.

pEXP441 (V1)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGLVQAGGSRLSCEASGNVDRIDAMGWFRQAPGK
pEXP366 (V2)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGLVQPGGSRLSCTASGSISSINAMGWYRQAPGS
pEXP457 (V4)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGLVQAGGSRLSCAASGLTFDTYAMGWFRQAPGK
pEXP368 (V4)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGLVQAGGSRLSCAASGLTFDTYAMGWFRQAPGK
pEXP455 (V1)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGLVQAGGSRLSCEASGNVDRIDAMGWFRQAPGK
pEXP444 (V2)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGLVQPGGSRLSCTASGSISSINAMGWYRQAPGS
pEXP445 (V3)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGLVQAGGSRLSCAASGLTFDTYAMGWFRQAPGK
	*****:*****
pEXP441 (V1)	QREFVGYISEGGI-LNYGDFVKGRFTISRDNKNTVYLQMSNLKSEDTGVYFCAASHWGTLLIKGI-EYW
pEXP366 (V2)	KREFVAHITNTGV-TEFADSVKGRFTISRDNKNTLYLQMDSLKPEDTAVYYCAATDWGTLLIKGI-DHW
pEXP457 (V4)	KREYVAAISWTGISTYYADIAKGRFTISRDNKNTLYLQMDSLKPEDTAVYYCAAQK--SLNVPAPWDYW
pEXP368 (V4)	KREYVAAISWTGISTYYADIAKGRFTISRDNKNTLYLQMDSLKPEDTAVYYCAAQK--SLNVPAPWDYW
pEXP455 (V1)	QREFVGYISEGGI-LNYGDFVKGRFTISRDDAKNTVYLQMSNLKSEDTGVYFCAASHWGTLLIKGI-EHW
pEXP444 (V2)	KREFVAHITNTGV-TEFADSVKGRFTISRDNKNTLYLQMDSLKPEDTAVYYCAATDWGTLLIKGI-DHW
pEXP445 (V3)	KREYVAAISWTGISTYYADIAKGRFTISRDNKNTLYLQMDSLKPEDTAVYYCAAQK--SLNVPAPWDYW
	:*:*. *: *: . *. *****:*****. ***. ***. * :*** :* : . : :*
pEXP441 (V1)	GQGTQVTVSSGPKE <del>EDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDNKKPGK</del>
pEXP366 (V2)	GQGTQVTVSSGPKE <del>EDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDNKKPGK</del>
pEXP457 (V4)	GQGTQVTVSSGPKE <del>EDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDNKKPGK</del>
pEXP368 (V4)	GQGTQVTVSSGPKE <del>EDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDNKKPGK</del>
pEXP455 (V1)	GQGTQVTVSSGPKE <del>EDNNKPGKEDNNKPGKED-</del>
pEXP444 (V2)	GQGTQVTVSSGPKE <del>EDNNKPGKED-</del>
pEXP445 (V3)	GQGTQVTVSSGPKE <del>EDNNKPGKED-</del>
	*****
pEXP441 (V1)	<del>EDGNKPGKEDNKKPGKEDGNKPGKEDGNKPGKEDGNVHVVKPGDTVNDIAKANGTTADKIAADNKLADK</del>
pEXP366 (V2)	<del>EDGNKPGKEDNKKPGKEDGNKPGKEDGNKPGKEDGNVHVVKPGDTVNDIAKANGTTADKIAADNKLADK</del>
pEXP457 (V4)	<del>EDGNKPGKEDNKKPGKEDGNKPGKEDGNKPGKEDGNVHVVKPGDTVNDIAKANGTTADKIAADNKLADK</del>
pEXP368 (V4)	<del>EDGNKPGKEDNKKPGKEDGNKPGKEDGNKPGKEDGNVHVVKPGDTVNDIAKANGTTADKIAADNKLADK</del>
pEXP455 (V1)	<del>-----NGIHVVKPGDTVNDIAKANGTTADKIAADNKLADK</del>
pEXP444 (V2)	<del>-----NGIHVVKPGDTVNDIAKANGTTADKIAADNKLADK</del>
pEXP445 (V3)	<del>-----NGIHVVKPGDTVNDIAKANGTTADKIAADNKLADK</del>
	***:*****
pEXP441 (V1)	NMIKPGQELVVVDKKQPHADANKAQA <b>LPETGEENPFIGTTVFGGLSLALGAALLAGRREL</b>
pEXP366 (V2)	NMIKPGQELVVVDKKQPHADANKAQA <b>LPETGEENPFIGTTVFGGLSLALGAALLAGRREL</b>
pEXP457 (V4)	NMIKPGQELVVVDKKQPHADANKAQA <b>LPETGEENPFIGTTVFGGLSLALGAALLAGRREL</b>
pEXP368 (V4)	NMIKPGQELVVVDKKQPHADANKAQA <b>LPETGEENPFIGTTVFGGLSLALGAALLAGRREL</b>
pEXP455 (V1)	NMIKPGQELVVVDKKQPHADANKAQA <b>LPETGEENPFIGTTVFGGLSLALGAALLAGRREL</b>
pEXP444 (V2)	NMIKPGQELVVVDKKQPHADANKAQA <b>LPETGEENPFIGTTVFGGLSLALGAALLAGRREL</b>
pEXP445 (V3)	NMIKPGQELVVVDKKQPHADANKAQA <b>LPETGEENPFIGTTVFGGLSLALGAALLAGRREL</b>
	*****

UspA signal peptide-Nb-ProtA /

**LPETG** sortase motif

**Figure S2.** Sequence alignment of the fusion protein (Signal peptide-FedF Nanobody-ProtA) expressed in *Lactococcus lactis*. The highlighted sections show the Usp signal peptide (green), anti-FaeG nanobody sequences (blue) and the ProtA sequences (red). The long and short ProtA repeat (consensus EDNNKPGK) sequences are indicated in italic. The LPETG C-terminal motif, recognized by the sortase enzyme, is shown in bold. Dashes were introduced to align the amino acid sequences.

pEXP362-1 (NbFed6) pEXP364-3 (NbFedF7) pEXP459 (NbFedF9) pEXP461 (NbFedF11) pEXP463 (NbFedF12) pEXP363 (NbFedF6) pEXP365 (NbFedF7) pEXP447 (NbFedF9) pEXP449 (NbFedF11) pEXP451 (NbFedF12)	MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGYTSGRDSMGWFRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGYTYSSNCMAWFRRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGYTSGRDSMGWFRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGNT-KSYWMGWFRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGYTSGRDSMGWFRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGYTYRKYCMGWFRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGYTYSSNCMAWFRRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGNRIYSMGWYRQAPGK MKKKIISAILMSTVILSAAAPLSGVYAQVQLQESGGGSVQAGGSRLSCAACSGNT-KSYWMGWFRQAPGK *****:*****:***** . *.*:***.****
pEXP362-1 (NbFed6) pEXP364-3 (NbFedF7) pEXP459 (NbFedF9) pEXP461 (NbFedF11) pEXP463 (NbFedF12) pEXP363 (NbFedF6) pEXP365 (NbFedF7) pEXP447 (NbFedF9) pEXP449 (NbFedF11) pEXP451 (NbFedF12)	EREGVACIDTSGIVNY-ADSVKGRFTISQDSAKKTLYLEMNSLKPEDTALYSCA-TGPFVYGRGCL--GQ EREGVACINSGGGTSYYADSVKGRFTISQDNAKDTVFLRMNSLKPEDTAIYYCA-L--SSNSVCPGHSV EREGVASINTRGGITYYYADSVKGRFTISRDNAKNTVSLQMNSLKPEDTATYYCAAVREATYSDNRCSVR DRELVSYIRFDGR-TYYDDSVKGRFTISQDNAKNTVFLQMNSLKPEDTAMYVCKIVSSGTGD----- EREGVAVIAGGGAFTYYAESVKGRFTISQDNTKDTVYLMANSLKPEDTALYYCA-LRTLNNGGIFLLNSP EREGVACIDTSGIVNY-ADSVKGRFTISQDSAKKTLYLEMNSLKPEDTALYSCA-TGPFVYGRGCL--GQ EREGVACINSGGGTSYYADSVKGRFTISQDNAKDTVFLRMNSLKPEDTAIYYCA---LSSNSVCPGHSV EREGVASINTRGGITYYYADSVKGRFTISRDNAKNTVSLQMNSLKPEDTATYYCAAVREATYSDNRCSVR DRELVSYIRFDGR-TYYDDSVKGRFTISQDNAKNTVFLQMNSLKPEDTAMYVCKIVSSGTGD----- EREGVAVIAGGGAFTYYAESVKGRFTISQDNTKDTVYLMANSLKPEDTALYYCA-LRTLNNGGIFLLNSP :*** : * * .* :*****:*****:*****: * * *****:***** * *
pEXP362-1 (NbFed6) pEXP364-3 (NbFedF7) pEXP459 (NbFedF9) pEXP461 (NbFedF11) pEXP463 (NbFedF12) pEXP363 (NbFedF6) pEXP365 (NbFedF7) pEXP447 (NbFedF9) pEXP449 (NbFedF11) pEXP451 (NbFedF12)	AFYSYWGQGTQTVTSSGPKEEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKED AWYNDWGQGTQTVTSSGPKEEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDGNKPGKED YTYYDWGQGTQTVTSSGPKEEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDGNKPGKED ---DYWGQGTQTVTSSGPKEEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKED SSFHYWGQGTQTVTSSGPKEEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKED AFYSYWGQGTQTVTSSGPKEEDNNKPGKED----- AWYNDWGQGTQTVTSSGPKEEDNNKPGKED----- YTYYDWGQGTQTVTSSGPKEEDNNKPGKED----- ---DYWGQGTQTVTSSGPKEEDNNKPGKED----- SSFHYWGQGTQTVTSSGPKEEDNNKPGKED----- *****:*****:*****:*****:*****:*****
pEXP362-1 (NbFed6) pEXP364-3 (NbFedF7) pEXP459 (NbFedF9) pEXP461 (NbFedF11) pEXP463 (NbFedF12) pEXP363 (NbFedF6) pEXP365 (NbFedF7) pEXP447 (NbFedF9) pEXP449 (NbFedF11) pEXP451 (NbFedF12)	NKKPGKEDGNKPGKEDNNKPGKEDGNKPGKEDGNVHVVVKPGDTVNDIAKANGTTADKIAAD NKKPGKEDGNKPGKEDNNKPGKEDGNKPGKEDGNVHVVVKPGDTVNDIAKANGTTADKIAAD NKKPGKEDGNKPGKEDNNKPGKEDGNKPGKEDGNVHVVVKPGDTVNDIAKANGTTADKIAAD NKKPGKEDGNKPGKEDNNKPGKEDGNKPGKEDGNVHVVVKPGDTVNDIAKANGTTADKIAAD NKKPGKEDGNKPGKEDNNKPGKEDGNKPGKEDGNVHVVVKPGDTVNDIAKANGTTADKIAAD -----GNGIHVVVKPGDTVNDIAKANGTTADKIAAD -----GNGIHVVVKPGDTVNDIAKANGTTADKIAAD -----GNGIHVVVKPGDTVNDIAKANGTTADKIAAD -----GNGIHVVVKPGDTVNDIAKANGTTADKIAAD *****:*****:*****:*****:*****:*****
pEXP362-1 (NbFed6) pEXP364-3 (NbFedF7) pEXP459 (NbFedF9) pEXP461 (NbFedF11) pEXP463 (NbFedF12) pEXP363 (NbFedF6) pEXP365 (NbFedF7) pEXP447 (NbFedF9) pEXP449 (NbFedF11) pEXP451 (NbFedF12)	NKLADKNMIKPGQELVVDDKKQ PANHANKA QAL <b>PETGEENPFIGTTVFGGLSLALGAALLAGRREL</b> NKLADKNMIKPGQELVVDDKKQ PANHANKA QAL <b>PETGEENPFIGTTVFGGLSLALGAALLAGRREL</b> *****:*****:*****:*****:*****:*****

UspA signal peptide-Nb-ProtA

**LPETG** sortase motif

**Table S1.** F18 *L. lactis* agglutination assay. Equal suspension volumes of *L. lactis* strains were mixed with *E. coli* 107/86 (F18<sup>+</sup>) and C95-72 (F4<sup>+</sup>, negative control) on agglutination slide for 5 min. Agglutination was scored on 0 – 5 scale.

<i>L. lactis</i> strain	Agglutination score	
	<i>E. coli</i> 107/86	<i>E. coli</i> C95-72
pEXP362-1 (NbFedF6) L	5	1
pEXP364-3 (NbFedF7) L	5	1
pEXP459 (NbFedF9) L	4	0
pEXP463 (NbFedF12) L	3	1
pEXP461 (NbFedF11) L	1	1
pEXP447 (Nb239) S	2	0
pEXP451 (Nb244) S	3	0
pEXP449 (Nb242) S	1	1
pEXP365 (Nb234) S	3	1
pEXP363 (Nb232) S	2	1

L and S refers to long and short protein A sequences, respectively. Agglutination scores: 5=Rapid uniform agglutination <15 sec; 4=Rapid uniform agglutination 15><30 sec; 3=Slow uniform agglutination 30sec ><1min; 2=Limited agglutination seen >1 min; 1=Apparent agglutination seen >1 min; 0>No agglutination >3 min.

**Table S2.** F4 *L. lactis* agglutination assay. Equal volumes of prepared *L. lactis* and *E. coli* strains C544-78, C95-72, C585-80 and 107/8 (control) were applied on the slide and mixed for 5 minutes by rocking. Agglutination was scored on 0 – 5 scale.

Strain	Agglutination score			
	C544-78 (F4ab)	C95-72 (F4ac)	C585-80 (F4ad)	107/86 (F18)
pEXP366 (V2) L	4	5	5	0
pEXP368 (V4) L	4	4	5	0
pEXP441 (V1) L	4	4	5	1
pEXP457 (V4) L	4	3	5	1
pEXP444 (V2) S	3	3	3	1
pEXP445 (V3) S	3	3	3	0
pEXP455 (V1) S	3	3	3	0

L and S refers to long and short anchor domain of protein A respectively. Agglutination scores; 5=Rapid uniform agglutination <15 sec; 4=Rapid uniform agglutination 15><30 sec; 3=Slow uniform agglutination 30sec ><1min; 2=Limited agglutination seen >1 min; 1=Apparent agglutination seen >1 min; 0>No agglutination >3 min.

**Table S3.** Effect of heat treatment on viability (CFSs/mL) and agglutination properties of *L. lactis* strains. Anti-FaeG Nb expressing *L. lactis* (pEXP368) was tested against F4<sup>+</sup> *E. coli* C544-78, anti-FedF Nb expressing *L. lactis* strain (pEXP362) was tested against the F18<sup>+</sup> *E. coli* 107/86. Agglutination was scored on 0–5 scale.

Temperature (°C)	<i>L. lactis</i> strain	Time (mins)	CFU/mL	Agglutination score
50	pEXP368	20	$3.8 \times 10^8$	5
		40	$7.5 \times 10^7$	5
		60	$4.6 \times 10^6$	5
50	pEXP362	20	$3.1 \times 10^7$	5
		40	$7.8 \times 10^6$	5
		60	$2.9 \times 10^5$	5
55	pEXP368	20	$1.8 \times 10^5$	5
		40	0	5
		60	0	5
55	pEXP362	20	$4.5 \times 10^3$	5
		40	$1.5 \times 10^3$	5
		60	0	5
60	pEXP368	20	0	5
		40	0	5
		60	0	5
60	pEXP362	20	0	5
		40	0	5
		60	0	5
65	pEXP368	20	0	3
		40	0	3
		60	0	3
65	pEXP362	20	0	3
		40	0	3
		60	0	3
70	pEXP368	20	0	1
		40	0	1
		60	0	1
70	pEXP362	20	0	1
		40	0	1
		60	0	1
Not heated	pEXP368		$3.3 \times 10^8$	5
Not heated	pEXP362		$6.6 \times 10^8$	5
DTT treated (5 mM)	pEXP368	20	$1.9 \times 10^8$	0
DTT treated (5 mM)	pEXP362	20	$1.0 \times 10^8$	0

Agglutination scores; 5=Rapid agglutination <15 sec; 4=Rapid agglutination 15><30 sec; 3=Slow agglutination 30sec ><1min; 2=Limited agglutination seen >1 min; 1=Apparent agglutination seen >1 min; 0=No agglutination >3 min.

**Table S4.** Average weight of piglets assigned to the 3 experimental groups. The piglets were weighed on days 0, 7 and 14. The average weights were comparable between the three groups. Group 1, Negative control group (not infected); Group 2, Positive group (infected and not treated); Group 3; Test group (infected with F4<sup>+</sup> ETEC and anti-FaeG Nanobodies on the surface of *L. lactis* added to the meals from day 0 to day 8).

Day	Treatment Group	N	Mean Weight	SE	95%CI	
					Lower	Upper
0	Group 1	5	4.84	0.472	3.892	5.788
	Group 2	4	5.23	0.785	3.649	6.800
	Group 3	8	5.15	0.317	4.513	5.787
7	Group 1	5	5.30	0.524	4.247	6.353
	Group 2	4	5.80	0.820	4.153	7.446
	Group 3	8	5.89	0.342	5.200	6.575
14	Group 1	5	6.06	0.610	4.816	7.264
	Group 2	4	6.48	0.930	4.606	8.344
	Group 3	8	6.59	0.368	5.848	7.237

**Table S5.** Meant percent weight gain between day 0–14. The mean percent weight gain was comparable between the three groups. Group 1, Negative control group (not infected); Group 2, Positive group (infected and not treated); Group 3; Test group (infected with F4<sup>+</sup> ETEC and anti-FaeG Nanobodies on the surface of *L. lactis* added to the meals from day 0 to day 8).

Treatment Group	Mean Weight	SD	Min	Max	p50
Group 1	19.64	6.402	9.1	26	21.3
Group 2	19.50	2.096	17.2	22	19.4
Group 3	21.81	4.790	12.7	29.5	21.6
Total	20.63	4.730	9.1	29.5	21.4

**Table S6.** Mixed effects logistic regression estimates of weight gain in experimental piglets with treatment and experiment days as fixed factors, and animal ID as random factor. Treatment group had no significant association weight gain while experiment day 14 was significant. All interactions between treatment groups and experiment days were not significant.

	Variable	Coef.	Std. Err.	p-value	95% CI	
					Lower	Upper
Treatment	Group 1	Referent				
Group	Group 2	.385	.7456728	0.606	-1.076492	1.846492
	Group 3	.31	.6337001	0.625	-.9320293	1.552029
Experiment day	Day 0	Referent				
	Day 7	.46	.1474821	0.002	.1709403	.7490597
	Day 14	1.2	.1474821	<0.001	.9109403	1.48906
Interaction:	Group 1	Referent				
Treatment/	Group 2/Day 7	.115	.2212232	0.603	-.3185895	.5485895
Experiment	Group 2/Day 14	.05	.2212232	0.821	-.3835895	.4835895
Day	Group 3/Day 7	.2775	.1880036	0.140	-.0909802	.6459802
	Group 3/Day 14	.2375	.1880036	0.206	-.1309802	.6059802
Intercept		4.84	.4971152	<0.001	3.865672	5.814328

**Table S7.** Mixed effects logistic regression estimates of Log10 CFU/g fecal bacteria shedding by experimental piglets, with treatment and experiment days as fixed factors and animal ID as random factor. Though not significant, estimated fecal bacterial shedding was lower in groups 2 and 3 by 0.24 and 0.28 logs, respectively. Analysis of the interaction between treatment groups and experiment day estimated a significant >1 log increase in fecal bacterial shedding in group 2 on days 5 -10 compared to reference group 1( $p<0.05$ ). In group 3, significant increase in fecal bacterial shedding ( $p<0.05$ ) was observed on days 3-6, >1 log increase was estimated for day 5 only. Group 1, Negative control group (not infected); Group 2, Positive group (infected and not treated); Group 3; Test group (infected with F4<sup>+</sup> ETEC and anti-FaeG Nanobodies on the surface of *L. lactis* added to the meals from day 0 to day 8).

	Variable	Coef.	SE	p-value	95% CI	
					Lower	Upper
Treatment	Group 1	Referent				
	Group 2	-.2448348	.3889586	0.529	-1.00718	.5175099
	Group 3	-.2799788	.3305512	0.397	-.9278473	.3678897
Interaction:	Group 1	Referent				
Treatment/	Group 2/Day -2	.2318059	.5326869	0.663	-.8122413	1.275853
Experiment	Group 2/Day 3	.6112077	.5326869	0.251	-.4328395	1.655255
Day	Group 2/Day 5	1.485867	.5176017	0.004	.4713859	2.500347
	Group 2/Day 6	1.243328	.5176017	0.016	.2288474	2.257809
	Group 2/Day 7	1.144239	.5176017	0.027	.1297586	2.15872
	Group 2/Day 8	1.135374	.5327436	0.033	.0912154	2.179532
	Group 2/Day 9	.8479532	.5327436	0.111	-.196205	1.892111
	Group 2/Day 10	1.193363	.5327436	0.025	.1492052	2.237522
	Group 2/Day 13	.3191032	.5176017	0.538	-.6953775	1.333584
	Group 3/Day -2	.327863	.457532	0.474	-.5688832	1.224609
	Group 3/Day 3	.8283653	.457532	0.070	-.0683809	1.725111
	Group 3/Day 5	1.055514	.4398768	0.016	.1933716	1.917657
	Group 3/Day 6	.8237689	.4462344	0.065	-.0508344	1.698372
	Group 3/Day 7	.4325005	.4398768	0.325	-.4296423	1.294643
	Group 3/Day 8	.3159568	.4575979	0.490	-.5809186	1.212832
	Group 3/Day 9	.2130587	.4575979	0.642	-.6838168	1.109934
	Group 3/Day 10	.2905302	.4575979	0.525	-.6063452	1.187406
	Group 3/Day 13	.3062692	.4398768	0.486	-.5558735	1.168412
Intercept		6.25745	.2593057	<0.001	5.74922	6.76568

**Table S8.** Mixed effects logistic regression estimates of immune response in experimental piglets with treatment and experiment days as fixed factors, and animal ID as random factor. While not significant, the analysis predicted a lower and increased immune response in groups 2 and 3, respectively. A similar pattern was observed for experiment days 7 and 14. A significant increase in immune response was estimated for group 3 on day 14. Immune response was measured as OD (optical density) in ELISA method.

	<b>Variable</b>	<b>Coef.</b>	<b>SE</b>	<b>p-value</b>	<b>95% CI</b>	
					<b>Lower</b>	<b>Upper</b>
Treatment	Group 1	Referent				
	Group 2	-.0706	.2449453	0.773	-.550684	.409484
	Group 3	.049525	.2081635	0.812	-.358468	.457518
Experiment day	Day 0	Referent				
	Day 7	-.01	.1982159	0.960	-.3984961	.3784961
	Day 14	.0872	.1982159	0.660	-.3012961	.4756961
Interaction:	Group 1	Referent				
Treatment/	Group 2/Day 7	.0715	.2973239	0.810	-.5112441	.6542441
Experiment Day	Group 2/Day 14	.5493	.2973239	0.065	-.0334441	1.132044
	Group 3/Day 7	.21225	.2526767	0.401	-.2829872	.7074872
	Group 3/Day 14	.884925	.2526767	<0.001	.3896878	1.380162
Intercept		.3726	.1632969	0.023	.052544	.692656